AR128622A1 - Inhibidores de la cinasa mek - Google Patents
Inhibidores de la cinasa mekInfo
- Publication number
- AR128622A1 AR128622A1 ARP230100462A ARP230100462A AR128622A1 AR 128622 A1 AR128622 A1 AR 128622A1 AR P230100462 A ARP230100462 A AR P230100462A AR P230100462 A ARP230100462 A AR P230100462A AR 128622 A1 AR128622 A1 AR 128622A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- substituted alkyl
- halo
- hydrogen
- cancer
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 4
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 3
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 abstract 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 208000030381 cutaneous melanoma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052698 phosphorus Inorganic materials 0.000 abstract 1
- 239000011574 phosphorus Substances 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000003708 skin melanoma Diseases 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
- C07F9/5325—Aromatic phosphine oxides or thioxides (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316607P | 2022-03-04 | 2022-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128622A1 true AR128622A1 (es) | 2024-05-29 |
Family
ID=85704077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100462A AR128622A1 (es) | 2022-03-04 | 2023-02-27 | Inhibidores de la cinasa mek |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11780862B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4486750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025507947A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119137130A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128622A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202342018A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023168203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
| WO2024220427A1 (en) * | 2023-04-17 | 2024-10-24 | Kinnate Biopharma Inc. | Treatment of cancer with a mek kinase inhibitor |
| WO2025032211A1 (en) | 2023-08-09 | 2025-02-13 | Pierre Fabre Medicament | Treatment of cancer with a raf inhibitor |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ATE344791T1 (de) | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| JP2002534515A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 1−複素環置換されたジアリールアミン |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| AU2482800A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| GB9910577D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Mex阻害物質としての5−アミド置換ジアリールアミン類 |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ES2444866T3 (es) | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| WO2007123939A2 (en) | 2006-04-19 | 2007-11-01 | Laboratoires Serono S.A. | Novel arylamino n-heteraryls as mek inhibitors |
| EP2279166A1 (en) | 2008-04-22 | 2011-02-02 | Bayer Schering Pharma Aktiengesellschaft | Substituted phenoxybenzamides |
| AU2009279940B2 (en) | 2008-08-04 | 2014-01-16 | Merck Patent Gmbh | Novel phenylamino isonicotinamide compounds |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| CN102649773A (zh) | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
| CN103570594A (zh) | 2012-08-01 | 2014-02-12 | 苏州迈泰生物技术有限公司 | 二芳基胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
| WO2020088390A1 (zh) * | 2018-10-29 | 2020-05-07 | 江苏先声药业有限公司 | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 |
| CN113660931B (zh) | 2018-11-20 | 2024-10-11 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物 |
| TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
-
2023
- 2023-02-24 TW TW112107027A patent/TW202342018A/zh unknown
- 2023-02-27 EP EP23711918.5A patent/EP4486750A1/en active Pending
- 2023-02-27 WO PCT/US2023/063338 patent/WO2023168203A1/en not_active Ceased
- 2023-02-27 US US18/175,074 patent/US11780862B2/en active Active
- 2023-02-27 JP JP2024552359A patent/JP2025507947A/ja active Pending
- 2023-02-27 AR ARP230100462A patent/AR128622A1/es unknown
- 2023-02-27 CN CN202380038101.5A patent/CN119137130A/zh active Pending
- 2023-06-15 US US18/335,803 patent/US12122800B2/en active Active
-
2024
- 2024-09-19 US US18/890,248 patent/US20250250293A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486750A1 (en) | 2025-01-08 |
| US20230279033A1 (en) | 2023-09-07 |
| US11780862B2 (en) | 2023-10-10 |
| WO2023168203A1 (en) | 2023-09-07 |
| JP2025507947A (ja) | 2025-03-21 |
| US20230416286A1 (en) | 2023-12-28 |
| US20250250293A1 (en) | 2025-08-07 |
| CN119137130A (zh) | 2024-12-13 |
| TW202342018A (zh) | 2023-11-01 |
| US12122800B2 (en) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| MX2021001486A (es) | Inhibidores prmt5. | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| UY38096A (es) | Inhibidores de arginasa y sus métodos de uso | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| MX2023003731A (es) | Compuestos de 3-[(1h-pirazol-4-il)oxi]pirazin-2-amina como inhibidores de hpk1, y uso de los mismos. | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR134040A1 (es) | Moduladores de mrgprx2 y métodos de tratamiento relacionados | |
| ECSP109934A (es) | Compuesto - 946 | |
| MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
| DOP2025000061A (es) | Péptidos cíclicos para atrapar interleucina-1 beta | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| AR126500A1 (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer | |
| CO2025018006A2 (es) | Formas sólidas de un inhibidor macrocíclico de farnesiltransferasa y formulaciones de estos, y métodos de preparación y uso del compuesto macrocíclico y sus formas sólidas | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer |